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Abstract
Microvascular endothelial cells cultured in three-dimensional hydrogel scaffolds form a network 
of microvessel structures when implanted subcutaneously in mice, inosculate with host vessels and 
over time remodel into large ectatic vascular structures resembling hemangiomas. When compared 
to infantile hemaniomas similarities were noted including a temporal progression from a 
morphological appearance of a proliferative phase to the appearance of an involuted phase 
mimicking the proliferative and involutional phases of infantile hemangioma. Consistent with the 
progression of a proliferative phase to an involuted phase, both the murine implants and human 
biopsy tissue exhibit reduced expression of Ajuba, YAP and Survivin labeling as they progressed 
over time.
Significant numbers of CD45+, CD11b+, Mac3+ mononuclear cells were found at the 2 week time 
point in our implant model which correlated with the presence of CD45+, CD68+ mononuclear 
cells observed in biopsies of human proliferative phase hemangiomas. At the 4 week time point in 
our implant model only small numbers of CD45+ cells were detected, which again correlated with 
our findings of significantly diminished CD45+, CD68+ mononuclear cells in human involutional 
phase hemangiomas. The demonstration of mononuclear cell infiltration transiently in the 
proliferative phase of these lesions suggests that the vascular proliferation and/or regression may 
be driven in part by an immune response.
Gross and microscopic morphological appearances of human proliferative and involutional 
hemangiomas and our implant model correlate well with each other as do the expression levels of 
Hippo pathway components (Ajuba and YAP) and Survivin and correlate with proliferation in 
these entities. Inhibitors of Survivin and Ajuba (which we have demonstrated to inhibit 
proliferation and increase apoptosis in murine hemangioma cell tissue culture) may have potential 
as other beneficial treatments for proliferating infantile hemangiomas.
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This implant model may have potential as a modest through-put screen for testing and 
development of therapeutics targeted at the proliferative phase of infantile hemangiomas, reducing 
the subsequent post-involutional scarring sometimes associated with these lesions.
Introduction
Implantation of a variety of cell types in three-dimensional scaffolds (biological and 
synthetic biocompatible) has been used extensively in a wide range of settings including 
attempts to improve structure and function of mesenchymal scaffolds in a variety of soft and 
hard tissue applications 1, 2, enhancement of vasculature following injury 3, enhancing 
repair/recovery of parenchymal tissue following injury 4 and production and delivery of 
soluble proteins 5. In addition, implantation of cells in three-dimensional scaffolds has been 
used to enhance survivability 6, investigate basic physiological and pathophysiological 
processes including angiogenesis 7, 8, cell migration and invasion 9, differentiation 10 and 
neoplasia 11. Using both biological (collagen and other ECM components) and 
biocompatible (hydrogels) scaffolds we have demonstrated their efficacy in combination 
with selected cell types as protein delivery vehicles 5, several angiogenesis studies and 
neural progenitor studies 10, 12, 13. In this report we found that when implanted 
subcutaneously, immortalized murine microvascular endothelial cells dispersed in a 
hydrogel scaffold undergo marked proliferation and became vascularized. Interestingly, over 
time (4weeks) these implants developed a lumpy, bulging appearance, resembling clusters of 
dilated vessels. These morphological changes that have occurred over time resemble the 
morphological changes observed in infantile hemangiomas as they progress from the 
proliferative to the involutional phase. In this report we also have documented the dynamic 
presence of immune cells and the expression of selected proteins known to modulate 
proliferation and survival in a wide range of cell types including endothelia in both the 
implants and infantile hemangiomas. Specifically, we illustrate changes in macrophage 
presence and expression of Ajuba, Survivin and YAP expression in both the clinical material 
and the murine implants and suggest that the murine implants may serve as a useful animal 
model of this entity, facilitating the development of therapeutics focused on blunting the 
proliferative phase and reducing the post-involutional scarring that sometimes accompanies 
the regression of these lesions.
Materials and Methods
Cell culture
Murine brain endothelial cells (BEC) were isolated from cerebral microvessels of C57BL/6 
wild type mice (WT-BEC) (The Jackson Laboratory, Bar Harbor, ME, USA) as shown 
previously 14–16. WT-BEC was cultured on 1.5% gelatin (Cat No. G8-500, Thermo Fisher 
Scientific Inc., Waltham, MA, USA) coated plates in brain endothelial cell media 
[Dulbecco’s Modified Eagle’s Medium (DMEM) with High Glucose (Life Technologies, 
Grand Island, NY, USA) containing 10% FBS, 2 mM L-glutamine, 0.1 mM nonessential 
amino acids, 1 mM sodium pyruvate, 10 mM HEPES (pH 7.4), 10−5 M β-mercaptoethanol, 
100 U/ml penicillin, and 100 μg/ml streptomycin (Life Technologies)] in 8% CO2 at 
37°C 9, 16. Cells were used passage 22 and cultured under normoxic (20% O2) condition.
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Dispersing endothelial cells in PEG/PLL hydrogels
We performed testing for endotoxin on the polymer precursors and have not observed 
indications consistent with endotoxin contamination. The inflammation we observed appears 
to be related to the cell-types used. When these same materials are used with other cell 
types, we do not see similar infiltration of inflammatory cells subcutaneously and in the 
spinal cord 3, 10, 12, 17, 18. Irgacure 2959 initiator was dissolved in brain endothelial cell 
media at a concentration of 5 mg/ml and filtered with 0.22 μm sterile syringe filter (Cat No. 
SLGP033RS, Millex-GP Syringe Filter Unit, 0.22 μm pore size hydrophilic polyethersulfone 
membrane; Merck Millipore, Billerica, MA, USA) before crosslinking. Poly(ethylene 
glycol)/poly(L-lysine) (PEG/PLL) macromers 10, 17–19 were dissolved at a concentration of 
10% (w/v) in the Irgacure 2959 initiator solution and mixed with WT-BEC at a 
concentration of 2.5 × 106 cells/ml. Aliquots of endothelial cells mixed with the macromer 
solution was placed under UV light for 10 min at 6 mW/cm2, which elicited formation of the 
gels with endothelial cells dispersed throughout.
Surgical procedures
Ten twelve week old C57 black mice (C57BL/6) (The Jackson Laboratory) were used for the 
subcutaneous implantation studies. Each mouse was anesthetized with an intra-peritoneal 
injection of ketamine (100 mg/kg) and xylazine (20 mg/kg). An incision of 10 mm in length 
was made through the skin overlying the thoracic spine and subcutaneous pockets were 
created bilaterally by blunt dissection under the skin. A round hydrogel disk (5 mm 
diameter) was implanted in each mouse, one in each pocket. The incision was closed with 
surgical clips and mice were maintained on a heating pad until they regained mobility. 
Following euthanasia, five Hydrogel implants were retrieved at 2 and 4 weeks respectively 
after implantation and fixed in 5% paraformaldehyde in 50 mM HEPES buffer (pH 7.3) 
overnight for histological analysis. All surgical procedures were approved by the Animal 
Care and Use Committees of Yale University (Animal Protocol No. 07366).
Histology
After fixation, excised implants were incubated in 15% and 30% Sucrose/PBS (pH 7.4) 
solutions sequentially overnight and embedded in PolyFreeze cryostat embedding medium 
(Cat No. 19636, Polysciences, Inc., Warrington, PA, USA). Ten μm thick sections were 
generated using a Cryotome™ FSE Cryostat (Thermo Fisher Scientific Inc., Waltham, MA, 
USA). Frozen sections were stained with Hematoxylin & Eosin (H&E) using Dako Mayer’s 
Hematoxylin (Lillie’s Modification) Histological Staining Reagent (Cat No. S3309, DAKO, 
Carpinteria, CA, USA) and Dako Eosin (Cat No. CS701, DAKO) for histopathological 
analysis.
Antibodies
Antibodies directed against mouse CD31 (PECAM-1) (affinity purified SL-4), raised in 
rabbit and purified as described elsewhere 20. Rat monoclonal antibodies against mouse 
CD31 [clone: MEC13.3] (Cat No. 550274), CD45 [30-F11] (Cat No. 550539), CD11b 
[M1/70] (Cat No. 550282), Mac3 [M3/84] (Cat No. 550292), and VE-cadherin (VEC) 
[11D4.1] (Cat No. 550548) were purchased from BD Biosciences (San Jose, CA, USA). 
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Rabbit polyclonal antibodies against Ki67 (Cat No. ab15580) were purchased from Abcam 
(Cambridge, MA, USA). Rabbit monoclonal antibodies against Survivin [71G4B7] (Cat No. 
#2808), YAP [D24E4] (Cat No. #8418), and phospho-YAP (Ser127) [D9W2I] (Cat No. 
#13008) (P-YAP) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, 
USA). A mouse monoclonal antibody against glucose transporter 1 (GLUT-1) [SPM498] 
(Cat No. ab40084) was purchased from Abcam (Cambridge, MA, USA). Mouse monoclonal 
antibodies against human CD31 [JC70A] (Cat No. M0823), a CD45 [2B11+PD7/26] (Cat 
No. M0701) and a monoclonal mouse anti human CD68 were purchased from DAKO. 
Rabbit polyclonal antibodies against human Ajuba (Cat No. HPA006171) were purchased 
from Sigma-Aldrich (Saint Louis, MO, USA). A rabbit polyclonal against human GLUT1 
was purchased from Cell Marque (Rocklin, CA).
Immunofluorescence
To prevent non-specific protein binding, frozen tissue sections were incubated with 5% 
normal goat serum (Cat No. 005-000-121, Jackson ImmunoResearch Laboratories, Inc., 
West Grove, PA, USA) in PBS (pH 7.4) containing 0.05% Triton X-100 (T-PBS) for 1 hour 
at room temperature. After blocking, sections were incubated with primary antibodies 
(CD31, CD45, CD11b, Mac3, and VEC diluted at 1:10 in T-PBS; CD31 (SL-4), YAP, and 
GLUT-1, diluted at 1:200; Survivin, diluted at 1:400; Ki67, diluted at 1:500; and phospho-
YAP, diluted at 1:2000 over night at 4°C and further with secondary antibodies [Alexa Fluor 
488 or 594-conjugated goat anti-rabbit IgG (H+L) or anti-rat IgG (H+L) (Life 
Technologies)], diluted at 1:100 in T-PBS for 2 hours at room temperature. Following three 
PBS washes slides were coverslipped with Dako Fluorescence Mounting Medium (Cat No. 
S3023, DAKO). Digital fluorescence images and phase-contrast microscopic photos were 
captured on an Olympus IX71 inverted microscope equipped with a MicroFire™ camera and 
PictureFrame™ 1.0 software for Macintosh (OPTRONICS, Goleta, CA, USA) and 
Photoshop CS2 software (Adobe, San Jose, CA, USA) on a Windows 7 computer.
Clinical cases
Representative proliferating and involuting phase cutaneous infantile hemangioma cases 
were collected for the present study from the Surgical Pathology files of the Yale University 
School of Medicine. The surgical samples were fixed in 10% formalin, processed routinely, 
and embedded in paraffin. Serial sections cut at 5 μm from paraffin blocks were used for 
H&E staining and immunohistochemistry. Briefly, a retrospective search of the pathology 
database was performed to identify cases of vascular tumors with the diagnosis of 
hemangioma. Over a ten year period a total of 58 cases were retrieved with the diagnosis. 
The original H&E slides were reviewed in a blinded fashion to see if there was concordance 
between the archived diagnosis and the diagnosis by the pathologists involved in this study. 
Out of these 58 cases, 13 cases were selected by consensus review, comprised of 6 infantile 
hemangiomas in the proliferative phase and 7 in the involutional phase. The selection was 
also partially based on the presence of sufficient tissue to perform additional 
immunohistochemical and micro-array studies. Following immuno-histochemical staining, 
the slides were reviewed in a blinded fashion from the original diagnosis by all the 
pathologists. Additional details regarding the cases are shown in Table 1. The study was 
approved by the institution’s IRB.
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Thirteen representative proliferating and involuting phase infantile hemangiomas were 
collected from the Surgical Pathology files of the Yale University School of Medicine. All 
cases were reviewed using clinical records and conventional H & E staining slides before 
selecting typical double-redundant histopathological areas (6 mm diameters, each) for the 
tissue microarray. Paraffin embedded tissue microarray slides were generated by the Yale 
University Pathology Department Tissue Services (YPTS) and used for 
immunohistochemistry.
Immunohistochemistry
Immunohistochemistry was performed using the Dako EnVision™ + Dual Link System-HRP 
(DAKO). For antigen-retrieval, sections were heated in citric acid buffer (pH 6.0) at 100°C 
for 10 min using Lab Vision PT Module (Thermo Fisher Scientific Inc.). The sections were 
treated with 0.3% hydrogen peroxide in methanol for 30 min at room temperature to block 
endogenous peroxidase activity and incubated with 5% normal goat serum in T-PBS for 1 
hour at room temperature to block non-specific protein binding sites. They were then 
incubated at 4°C with the primary antibodies diluted at 1:40 (anti-human CD31), 1:50 (anti-
Ajuba and CD45), 1:200 (anti-YAP), 1:400 (anti-Survivin), 1:2 (anti-GLUT1) and 1:16 
(anti-CD68) in T-PBS. After overnight incubation, the sections were incubated with 
EnVision reagents for 1 hour at room temperature and treated with Dako Liquid DAB+ 
Substrate Chromogen System (Cat No. K3468, DAKO) to visualize the reaction products. 
Sections were counterstained with Dako Mayer’s Hematoxylin (Lillie’s Modification) 
Histological Staining Reagent (DAKO). Digital immunohistochemical images were captured 
on an Olympus IX71 inverted microscope equipped with a MicroFire™ camera and 
PictureFrame™ 1.0 software for Macintosh (OPTRONICS) and Photoshop CS2 software 
(Adobe) on a Windows 7 computer.
Results
Implanted endothelial cell hydrogel scaffolds exhibit inosculation and dynamic remodeling 
over time
Following subcutaneous implantation, all the three-dimensional endothelial cell containing 
hydrogel scaffolds elicited ingrowth of host vessels and inosculation with tube-like 
structures within the scaffolds, exhibiting a vascularized phenotype (Figure 1A, upper 
panel). Additionally, a robust inflammatory infiltrate mainly composed of mononuclear cells 
is noted infiltrating the implant at the two week time point (Figure 1A, second, third and 
fourth panels). At the four week time point the implants have taken on a bulging, bumpy 
appearance with a deep red-purple color (Figure 1B, upper panel). Large ectatic blood-filled 
structures were noted, separated by connective tissue septa containing several microvascular 
structures and a paucity of infiltrated immune cells (Figure 1B, second, third and fourth 
panels).
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Implants exhibit dynamic immune cell infiltration in the peri-implant area over time
At the two week time point, immunofluorescence staining with CD31 confirmed the robust 
neovascularization in peri-implant areas elicited by the implant (Figure 2A, left column). 
Double staining with CD45, CD11b and Mac3 (Figure 2A, (middle column, first, second 
and third rows, respectively) revealed an intense labeling of mononuclear immune cells 
throughout the granulation tissue comprising the peri-implant area. Merged images of CD31 
and CD45, CD11b and Mac3 (Figure 2A, left column) illustrate immune cell infiltration in 
close proximity to the microvasculature. High power insets of the merged images reveal an 
intimate association between the vasculature and the mononuclear immune cells.
At the four week time point there was considerable remodeling of the implants. Specifically, 
ectatic blood-filled spaces were lined by endothelial cells and the intervening connective 
tissue septa exhibited a reduced density of microvasculature and a dramatic reduction in 
mononuclear immune cell infiltration. Occasional immune cells were noted adherent to and 
in close proximity with the endothelial cells lining the blood-filled spaces as evidenced by 
CD31 (Figure 2B, left column), CD45 and CD11b (Figure 2B, middle column) double 
staining. Merged images (Figure 2B, right column) further illustrate this co-localization.
Proliferative pathway components are expressed in a dynamic fashion in and around the 
implants over time
In order to investigate potential drivers of the early transient proliferative response in the 
implant tissue we stained the tissues with CD31, VE-cadherin, Ki67, Survivin, YAP, and 
phospho-YAP. At the two week time point, immuno-co-localization with CD31 (Figure 3) 
and VE-cadherin (first row) illustrates their co-localization in peri-implant areas (left side of 
the yellow dashed line) but a lack of VE-cadherin with CD31 positive vessels deeper within 
the implant (right of the yellow dashed line, circled endothelial cells), indicative of a lack of 
endothelial differentiation in this area at this time point. Immuno-co-localization with CD31 
and Ki67 (second row) revealed Ki67 positivity in mononuclear immune cell nuclei with 
none being detected in endothelial cell nuclei in peri-implant or implant areas (circled 
endothelial cells) at this time point. Survivin (third row) displayed a similar localization 
pattern as Ki67 with modest immune cell localizations in peri-implant areas (boxed area = 
inset) and no appreciable labeling in implant areas (circled endothelial cells). YAP 
localization (fourth row) appeared to be a mix of immune cell and endothelial cell 
localizations (boxed inset) in the peri-implant area and implant areas (circled endothelial 
cells). Phospho-YAP (fifth row) displayed a similar localization pattern as YAP, while 
having fewer positive immune cells. At the two week time point, immuno-co-localization 
with CD31 (Figure 3) and GLUT1 (sixth row) illustrates their co-localization in peri-implant 
areas (left side of the yellow dashed line) but a lack of GLUT1 in CD31 positive vessels 
deeper within the implant (right of the yellow dashed line, circled endothelial cells), 
indicative of a lack of endothelial differentiation in this area at this time point, similar to 
what was observed for VE-cadherin.
To further delineate the cell population(s) expressing Survivin and YAP, we double-labeled 
the tissues with anti-CD45 and anti-Survivin or anti-YAP. As noted in Figure 4, at the two 
week time point Survivin co-localization with CD45 positive mononuclear cells is minimal 
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(first row). In contrast, YAP co-localization with CD45 positive cells appears moderate in 
peri-implant areas (second row). Additionally, similar to staining illustrated in Figure 3, 
modest Survivin co-localization with CD45 positive cells was noted (top row). In contrast, 
YAP co-localization was noted with both CD31 positive endothelial cells (Figure 3) as well 
as with CD45 positive immune cells (bottom row).
At the four week time point, immuno-co-localization with CD31 (Figure 5, left column) and 
VE-cadherin (first row) illustrates their co-localization in endothelial cells lining the ectatic 
blood-filled spaces. Immuno-co-localization with CD31 and Ki67 (second row) revealed 
Ki67 positivity in two endothelial lining cells (arrows). Survivin expression (third row) was 
not detected at this time point (third row). Robust YAP expression appeared limited to the 
lining endothelial cells (inset) but absent in the dense connective tissue septa. Modest 
Phospho-YAP expression (fifth row) also appeared limited to the lining endothelial cells 
(inset) but absent in the dense connective tissue septa. At the four week time point, immuno-
co-localization of CD31 and GLUT1 (sixth row) appears in a patchy, irregular pattern 
restricted to the lining endothelial cells and more intensely in endothelial cells comprising 
microvessels in the dense connective tissue septa (inset).
Survivin and Hippo-pathway component expression in proliferative (A) and involuting (B) 
infantile hemangioma mirrors expression levels in Hydrogel-endothelial cell implants 
(Figure 6)
Histological and immunohistochemical analyses of proliferative phase infantile 
hemangiomas revealed similarities to the hydrogel-endothelial cell two week implants in 
their CD31, GLUT1, Ajuba, Survivin, YAP and CD45 expressions. Low power (left panel) 
and high power (second panel) H & E stained sections revealed solid regions consisting of 
small vascular lumina lined by flattened endothelial cells among clusters of mononuclear 
cells in a scant stroma (lower half of the image), illustrative of the proliferative phase 
(Figure 6A1-3). Labeling with anti-CD31 revealed robust staining of endothelial cells lining 
the lumina and single endothelial cells present throughout the lower half of the image and 
predominately endothelial cell lining cells in the upper half of the image (left two panels, 
second row, lower half of the image and the inset) (Figure 6A3-6). As observed for CD31 
staining, GLUT1 exhibited robust staining of endothelial cells lining the lumina and 
occasional single endothelial cells present throughout the image and the inset, predominately 
endothelial cell lining cells in the upper half of the image (left two panels, third row and the 
inset) (Figure 6A7-9). Labeling with anti-Ajuba revealed predominately nuclear and modest 
cytoplasmic staining of endothelial lining cells and single endothelial cells throughout the 
entire section (Figure 4A10-12). Labeling with anti-Survivin also revealed predominately 
nuclear staining of endothelial lining cells and single endothelial cells throughout the entire 
section (Figure 6A13-15). YAP staining was also found to be present in both the nuclei and 
cytoplasm of the luminal lining endothelial cells and occasional single cells in between the 
lumina (Figure 6A16-18). CD45 staining revealed robust staining of many mononuclear cells 
present throughout the more solid areas of the proliferative hemangioma (Figure 6A19-21). 
To support our hypothesis that the CD45 positive cells were macrophages we stained 
representative infantile hemangioma lesions with anti-CD68. Examination of the stained 
tissue revealed significant numbers of CD68 positive cells interspersed among endothelial 
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cells and the formed vessel segments in lesional tissue (Figure 6A22-24). CD3 staining 
revealed a very small number of CD3 positive cells interspersed the endothelial cells and 
vessel segments of lesional tissue (Figure 6A25-27). As expected, staining the hemangioma 
specimens with Ki67 revealed robust nuclear staining in the proliferative specimens (Figure 
6A28-30).
Histological and immunohistochemical analyses of involuted phase infantile hemangiomas 
revealed similarities to the hydrogel-endothelial cell four week implants in their CD31, 
Survivin, YAP, CD45 and GLUT1 expressions. Low power and high power H & E stained 
sections revealed various sized vascular lumina lined by flattened endothelial cells 
interspersed in a dense fibrous stroma having an occasional cell interspersed throughout the 
stroma. (Figure 6B1-3), illustrative of the involuted phase. Labeling with anti-CD31 again 
revealed robust staining of endothelial cells lining the lumina and rare single endothelial 
cells interspersed throughout the stroma (Figure 6B4-6). Labeling with anti-GLUT1 
exhibited moderate staining of endothelial cells lining the lumina (Figure 6B7-9). Labeling 
with anti-Ajuba revealed very modest cytoplasmic staining of endothelial lining cells (Figure 
6B10-12). Labeling with anti-Survivin was not detectable (Figure 6B13-15), as was YAP 
staining (Figure 6B16-18). CD45 staining in involuted hemangiomas exhibit moderate 
staining of only a few mononuclear cells in the connective tissue stroma and occasional 
positive cells in the lumina of vessels in the tumor (Figure 6B19-21). Examination of the 
stained tissue also revealed rare CD68 positive cells interspersed among endothelial cells 
and formed vessel segments in lesional tissue (Figure 6B22-24). CD3 staining also revealed 
rare CD3 positive cells interspersed among the vessel segments of lesional tissue (Figure 
6B24-27). In contrast to the proliferative specimens, staining of the involutional hemangioma 
specimens with Ki67 revealed very modest nuclear staining (Figure 6B28-30).
Expression levels of Ajuba (and to a lesser extent YAP, Survivin and CD45) in Infantile 
Hemangioma correlate with the proliferative and involuting phases of samples contained 
in our tissue microarray
Immunohistological analyses of representative proliferative and involuting phase infantile 
hemangiomas from our 6mm double redundant tissue microarray using anti-Ajuba, -
Survivin, -Yap, and -CD45 reagents revealed that in the proliferative phase Ki67, Ajuba, 
Survivin, YAP and CD45 expression was greater than that observed in the involuted phase of 
infantile hemangiomas (data not shown).
This prompted analyses of the thirteen proliferative and involuting phase infantile 
hemangiomas included in our tissue microarray, using anti-Ki67 (not shown), -Ajuba, -YAP, 
-Survivin and -CD45 reagents. This staining revealed that the staining intensities noted in 
the proliferative and involuted phases of infantile hemangiomas was observed as a 
continuum, with Ajuba intensity correlating with the degree of proliferative histology 
(Figure 7, first and fifth columns), with cases one through seven correlating with a 
proliferative phenotype. Cases eight and nine displayed an intermediate staining pattern 
consistent with lesions in transition from proliferative to involuting phase and cases ten 
through thirteen displayed staining patterns consistent with involuting phase hemangiomas. 
While exhibiting similar expression ranges (albeit at less intense levels compared to Ajuba 
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staining), YAP (second and sixth columns), Survivin (third and seventh columns) and CD45 
(fourth and eighth columns) expressions were also demonstrative of a continuum of staining 
of infantile hemangiomas from proliferative (more intense) to involuting (decreased 
intensity) phases.
Upon comparing our immunohistochemical- and morphological-based diagnoses (Figure 7) 
with the CoPath diagnoses (Table 1, CoPath Dx), we found agreement with all but two cases 
(# 3 and 7) in which our immunochemical data placed them in the proliferative phase (Table 
1, Surv/Hippo Anal). Additionally, our analysis placed cases 8 and 9 in a transitional phase, 
expressing areas consistent with both proliferative and involutional phases.
Discussion
Infantile hemangiomas are common benign tumors in childhood, being diagnosed in as 
many as 10% of children under one year of age, with increased incidence in premature 
infants and females 21–23. Hemangiomas share a common feature of robust proliferation at 
the initial stages during their development followed by a regressive phase and scar 
formation 22. The great majority of these lesions do not require any intervention. However, 
facial lesions and lesions of large size sometimes do require treatment which has included 
systemic steroids, immune regulators, Interferon alpha, propranalol, radiation, laser 
treatment and surgery 22, 24–27, all having some potential side effects. Several underlying 
mechanisms involved in the development of infantile hemangiomas have been proposed and 
discussed, although a definitive mechanism is still elusive 23, 26, 28–31. Evidence has been 
accrued suggesting that the placenta may be related to infantile hemangioma in that these 
lesions have been associated with mothers that have undergone chorionic villus sampling. 
While interesting, investigators have not observed maternal-fetal chimerism and that the 
genotype of the lesions is that of the child, not the mother. Another theory also involving the 
placenta is based on the observations that tumor derived secreted substances can elicit 
changes in in specific organs and tissues that predispose them to metastases 32, 33 (in this 
case the fetal placenta or a chorangioma would be the tissue source of the putative 
substances and the hemangioma precursor cells). In addition, the cell of origin of 
hemangiomas has been postulated to be the result of a mutation(s) in a precursor cell as 
investigators have determined that cells isolated from hemangioma tissue have exhibited 
clonality 23, 34. Additionally, local and systemic perturbations in the individual during 
infancy may predispose to the development of hemangiomas 35. Specifically, hypoxia has 
been suggested as a driver leading to upregulation of transcription factors and chemokines 
which can elicit recruitment of endothelial progenitor cells and hemangioma 
development 35. While contributing to our understanding of hemangiomas, no single theory 
adequately explains all pathobiology of these lesions and highlights the complexity of these 
lesions 27, 30, 31.
Our findings that the kinetics of our three dimensional subcutaneous implanted hydrogel-
endothelial cell cultures mimicked the proliferative and involutional phases of human 
infantile hemangiomas prompted us to further characterize and compare the cellular 
composition of our murine model and the human counterpart. Surprisingly, we noted that 
many of the cells comprising the murine implants at the two week time point were not 
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endothelial, but expressed the markers of mononuclear cells, namely CD45, CD11b and 
Mac3. The inflammation we observed appears to be related to the cell-types used. When 
these same materials are used with other cell types, we do not see a similar infiltration of 
inflammatory cells 3, 10, 12, 17, 18. Analysis of proliferative phase human infantile 
hemangiomas also revealed the presence of CD45 and CD68 positive cells interspersed 
among single and lumen-forming endothelia. When the murine implants were assessed for 
the presence of CD45, CD11b and Mac3 at the four week time point a significantly reduced 
number of these cells were noted. Similarly, analysis of involutional phase human infantile 
hemangiomas revealed a significantly reduced presence of CD45 and CD68 positive cells 
interspersed among lumen-forming endothelia. These similarities between the kinetics of our 
murine subcutaneous implants and the human biopsies suggests a possible dynamic, 
temporal role for immune cells in the proliferative phase of infantile hemangiomas, either as 
an initiating cell in the proliferative phase, and/or a cell involved in down regulating the 
proliferative response or inhibiting proliferative signals following an initiating event. 
Precedence for such a role for monocytes/macrophages has been well-documented during 
the inflammatory process 36, 37 as well as during developmental/regenerative 
processes 36, 38, 39 and has been observed and documented in infantile 
hemangiomas 27, 40, 41. Our finding of increased numbers of CD45+, CD58+ cells in 
proliferating infantile hemangiomas compared to involuting infantile hemangiomas provides 
additional evidence suggesting the potential importance of these cells and their interactions 
with endothelial cells in the biological behavior of this entity. Additionally, this observation 
adds another potential mechanism explaining, in part, yet another aspect of local and/or 
systemic perturbations in the individual during infancy (which may evoke an immune 
response) and thus may predispose to the development of hemangiomas and/or their 
involution. The presence of specific myeloid cells has been postulated as playing roles in the 
proliferative phase and involution noted in the life cycle of infantile hemangiomas 27, 41. It 
has been reported that treatment with an immune regulator, imiquimod cream, caused 
accelerated regression of proliferative hemangiomas 27, consistent with a role of immune 
cells in the modulation of the proliferative phase of these lesions. Regarding modulation of 
the involutional phase and subsequent scarring or fibrosis of infantile hemangiomas, other 
than the association of involution with age there has been no mechanism demonstrated 42.
In addition, in light of our recent findings demonstrating a role for Survivin and Hippo 
pathway components as modulators of endothelial and hemangioendothelioma proliferation 
and apoptosis in vitro 9, 14, we embarked upon an assessment of components of these 
pathways in our murine model and in patient samples of infantile hemangioma. Interestingly, 
we found early (two week) implants and proliferating infantile hemangiomas exhibited more 
robust Survivin, YAP and Ajuba staining than late (four week) implants and involutional 
infantile hemangiomas. Of these molecules, Ajuba (an inhibitor of LATS/12, a kinase that 
phosphorylates YAP, targeting it to the proteosome, reducing Hippo activity, eliciting 
increased proliferation and reduced apoptosis 9, 14, gave the best correlation with the phase 
of the hemangiomas. Interestingly, Survivin has been examined in canine vascular tumors 43 
and found not to be increased in hemangiomas. However, the data shown in this report 43 is 
illustrative of an involutional phase hemangioma, which is consistent with our results. 
Overall, our data are consistent with the possibility that the Survivin and Hippo pathways are 
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modulators of proliferation and apoptosis in both the murine and human entities and that 
inhibition of either or both of these pathways (inhibition of Survivin activity and/or 
neutralization of Hippo pathway inhibitors) may be potential therapeutic targets 44. As we 
have recently noted, a small molecule Survivin inhibitor YM155, exhibiting modest side 
effects and currently under study in clinical trials for solid tumors, is an effective modulator 
of hemangioendothelioma (EOMA) cells in culture while having no appreciable effect on 
wildtype endothelial cells in vitro 9. This small molecule inhibits Survivin expression by 
interfering with Sp1 binding to the Survivin promoter 45. Inhibiting Survivin expression was 
found to induce expression of VE-cadherin and CD31, facilitating adherens junction 
formation, thus enhancing contact inhibition mediated reduction of proliferation, inhibiting 
Ajuba expression, resulting in activation of the Hippo pathway, reducing nuclear YAP levels, 
reducing proliferation and increasing apoptosis 9. Thus, we speculate that selective 
inhibition of Survivin and/or inhibitors of the Hippo pathway may have potential as another 
beneficial treatment for proliferating infantile hemangiomas that have significant 
pathological potential, reducing subsequent scar formation and disfigurement as well as for 
other more aggressive vascular tumors. Lastly, our murine model may have potential as a 
model which will allow for the elucidation of the underlying mechanisms driving the 
proliferative and involutional phases of this entity and as a modest through-put screen for 
compounds targeting these and other signaling pathways, leading to human phase trials.
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Figure 1. Macroscopic images and histopathology of subcutaneous hydrogel implants for 2 and 4 
weeks
(A) The macroscopic image of hydrogel implanted for 2 weeks illustrates the apparent 
vascularization of the hydrogel implant (blue dashed line), as evidenced by its pinkish color, 
and a large feeder vessel at 10 o’clock and a smaller ones at 8 and 11 o’clock and running 
along the border of the implant from 2 to 5 o’clock. (Left panel, top row). Scale bar, 1 mm. 
Low power H&E cross-section images of this tissue (Left panel, second row from top), 
reveal a circumscribed area representing the implant which has been partially infiltrated with 
inflammatory cells and granulation tissue that is also present surrounding the implant. 
Asterisks denote the skin surface. Scale bar, 1 mm. Intermediate (Left panel, third row) and 
high power (Left panel, fourth row) images illustrate the ingrowth of inflammatory cells and 
granulation tissue into the implant proper. The yellow dotted lines represent the borderline 
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between hydrogel and granulation tissue. Scale bars, 200 μm. (B) In contrast to the 
macroscopic appearance of the two week implants, the macroscopic image of a 
representative hydrogel implant after 4 weeks of implantation reveals a dark purple lobulated 
globular structure with occasional feeder vessels coursing toward and through it. Low power 
H&E cross-section images of this tissue (Right panel, second row), reveals the formation of 
several large ectatic blood-filled vascular spaces in the dermis, underlying the surface skin. 
These hemangioma-like lesions exhibited clear margins. Asterisks denote the skin surface. 
Scale bar, 10 mm. Intermediate (Right panel, third row) and high power (Right panel, fourth 
row) images illustrate fibrovascular cords forming the walls and separating the ectatic blood-
filled vascular spaces. Also noted, in contrast to the two-week implants was a paucity of 
inflammatory infiltrate. Scale bars, 200 μm.
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Figure 2. Dynamic Inflammatory cell recruitment and angiogenesis in peri-implant tissue and 
implants over time
(A) Immunofluorescence imaging of CD31 (red, left column), CD45 (green, middle column, 
top row), merged CD31/CD45/DAPI (right column, top row), CD11b (green, middle 
column, second row), merged CD31/CD11b/DAPI (right second row from top), Mac3 
(green, middle bottom row), and merged CD31/Mac3/DAPI (right column, third row) in 
hydrogel implants and surrounding tissues following 2 week implantations. Yellow dashed 
lines represent the borderline between hydrogel and surrounding granulation tissue. Inserts 
in merged panels illustrate the infiltration of CD45-CD11b-Mac3 positive mononuclear 
inflammatory cells in the peri-implant areas. Scale bars, 50 μm.
(B) Hydrogel implants after 4 week implantations. Immunofluorescence imaging of CD31 
(red, left column), CD45 (green, middle column, top row), merged CD31/CD45/DAPI (right 
column, top row), CD11b (green, middle second row from top), and merged CD31/CD11b/
DAPI (right second row from top). There were few CD45 and CD11b positive mononuclear 
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inflammatory cells throughout the fibrous granulation tissue scaffolding separating the 
dilated vascular structures. Scale bars, 50 μm.
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Figure 3. Dynamic Survivin and Hippo-pathway component expression in the in the peri-implant 
and implant areas at the two week time point
Hydrogel implants after 2 weeks. Immunofluorescence staining for CD31 (red, left column), 
VE-cadherin (VEC) (green, middle column, top row), merged CD31/VEC/DAPI (right 
column, top row), Ki67 (green, middle column, second row), merged CD31/Ki67/DAPI 
(right column, second row), Survivin (green, middle column, third row), merged CD31/
Survivin/DAPI (right column, third row), YAP (green, middle column, fourth row), merged 
CD31/YAP/DAPI (right column, fourth row), phospho-YAP (P-YAP) (green, middle 
column, fifth row), and merged CD31/P-YAP/DAPI (right column, fifth row), GLUT1 
(green, middle column, sixth row), and merged CD31/GLUT1/DAPI (right column, sixth 
row). Yellow dashed lines represent the borderline between hydrogel and granulation tissue. 
Circles denote CD31 positive endothelial cells in the implant areas. Inserts in merged panels 
illustrate that Survivin positive proliferating cells infiltrated into the perivascular area as did 
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occasional Ki67-positive cells. YAP was localized in nuclear and cytoplasmic localizations 
in the microvascular endothelial cells as well as in the cytoplasm of mononuclear infiltrating 
cells around blood vessels (Insert, right panel, fourth row). P-YAP was localized in the 
cytoplasm of newly formed blood vessels as well as infiltrating mononuclear cells (Insert, 
right panel, fifth row). GLUT1 was found to be colocalized with CD31 in endothelial cells 
(Insert, right panel, bottom row). Scale bars, 50 μm.
Tsuneki et al. Page 19













Figure 4. Survivin and Hippo-pathway component expression in the mononuclear cells in the 
implant
Hydrogel implants after 2 weeks. Immunofluorescence staining for Survivin (red, left 
column, top row), CD45 (green, middle column, top row), merged Survivin/CD45/DAPI 
(right column, top row), YAP (red, left column, second row), CD45 (green, middle column, 
second row), merged YAP/CD45/DAPI (right column, second row). Yellow dashed lines 
represent the borderline between hydrogel and granulation tissue. Insets in merged panels 
denote CD45 positive mononuclear cells in the implant areas. Scale bars, 50 μm.
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Figure 5. Dynamic Survivin and Hippo-pathway component expression in the in the peri-implant 
and implant areas at the four week time point
In contrast to the two week time point, hydrogel implants after 4 weeks exhibited differential 
localizations and expression levels of VE-cadherin, Ki67, Survivin, Hippo pathway 
components (YAP and phosphor-YAP) and GLUT1. Immunofluorescence staining for CD31 
(red, left column), VE-cadherin (VEC) (green, middle column, top row), merged 
CD31/VEC/DAPI (right column, top row), Ki67 (green, middle column, second row), 
merged CD31/Ki67/DAPI (right column, second row), Survivin (green, middle column, 
third row), merged CD31/Survivin/DAPI (right column, third row), YAP (green, middle 
Tsuneki et al. Page 21













column, fourth row), merged CD31/YAP/DAPI (right column, fourth row), phospho-YAP 
(P-YAP) (green, middle column, fifth row), merged CD31/P-YAP/DAPI (right column, fifth 
row), GLUT1 (green, middle column, bottom row) and merged CD31/GLUT1/DAPI (right 
column, bottom row and Inset) revealed modest staining of Ki67 (arrows) and Survivin, 
robust YAP and moderate P-YAP staining in endothelial cells. In contrast to the 2 week 
implants the 4 week implant connective tissues exhibited very modest CD31, VE-cadherin 
Survivin, YAP and P-YAP staining. Interestingly. GLUT was localized to the 
microvasculature in the connective tissue septa, colocalizing with CD31 but was absent from 
the endothelia lining the ectatic blood-filled spaces (left column, bottom row and Inset). 
Scale bars, 50 μm.
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Figure 6. Immunofluorescence analysis of proliferative (A) and involutional (B) infantile 
hemangiomas
A) H&E stains of proliferative lesions exhibit solid areas comprised of single endothelial 
cells and endothelial cells forming small vascular structures, interspersed with mesenchymal 
and immune cells (A1-3). The endothelial cells labeled intensely with anti-CD31 and anti-
GLUT1 (A4-9). Proliferative lesions exhibited intense nuclear and cytoplasmic labeling with 
anti-Ajuba (A10-12) and robust nuclear labeling with anti-Survivin (A13-15) and YAP 
(A16-18). In addition, the proliferative lesions exhibited labeling with anti-CD45 and CD68, 
consistent with macrophages (A19-24). Additionally, these lesions exhibited occasional 
labeling with anti-CD3, indicative of T lymphocytes (A25-27). Proliferative lesions exhibited 
Tsuneki et al. Page 23













intense nuclear and labeling with anti-Ki67 (A28-30). Scale bars: A1,4,7,10,13,16,19,22,25,28 = 
100 μm; A2,5,8,11,14,17,20,23,26,29 = 50 μm; A3,6,9,12,15,18,2,,224,27.30 = 25 μm.
B) H&E stains of involutional lesions exhibit clusters of endothelial cell lined tubes 
interspersed in a dense fibrous mesenchyme comprised of occasional microvascular vessels 
and fibroblastic cells (B1-3). Endothelial cells labeled intensely with anti-CD31 and anti-
GLUT1 (B4-9). In contrast to the proliferative lesions, the involutional lesions exhibited very 
modest to undetectable labeling with anti-Ajuba (B10-12), Survivin (B13-15) and YAP 
(B16-18). Similarly, antiCD45, CD68 and CD3 labeling labeled rare cells in the involutional 
lesions (B19-27). In contrast to the proliferative lesions, the involutional lesions exhibited 
modest nuclear labeling with anti-Ki67 (B28-30). Scale bars: B1,4,7,10,13,16,19,22,25,28 = 100 
μm; B2,5,8,11,14,17,20,23,26,29 = 50 μm; B3,6,9,12,15,18,2,,224,27,30 = 25 μm.
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Figure 7. YAP, Ajuba and CD45 expression levels in thirteen proliferative and involuting phase 
Infantile Hemangioma samples contained in our vascular tumor tissue microarray
Infantile hemangiomas stained for Ajuba (first column, YAP (second column), Survivin 
(third column) and CD45 (fourth column) were ranked according to Ajuba intensity (1 – 13), 
with (1 to 7) scored as proliferative and (8 and 9) scored as intermediate, have features of 
both proliferating and involuting hemangiomas and (10 to 13) scored as involuting infantile 
hemangiomas according to their Ajuba intensity in our double redundant tissue array. 
Although staining intensities of YAP, Survivin and CD45 are much lighter, they to reflect 
similar degrees of staining intensity and are cocsistent with the Ajuba scoring. Scale bars: 
first and second columns = 100 μm, insets = 20 μm; third and fourth columns = 30 μm.
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